230 related articles for article (PubMed ID: 10656456)
1. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
[TBL] [Abstract][Full Text] [Related]
2. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
Ueno NT; Yu D; Hung MC
Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
[TBL] [Abstract][Full Text] [Related]
4. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
5. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
Zhang Y; Yu D; Xia W; Hung MC
Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
[TBL] [Abstract][Full Text] [Related]
7. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.
Bartholomeusz C; Itamochi H; Yuan LX; Esteva FJ; Wood CG; Terakawa N; Hung MC; Ueno NT
Cancer Res; 2005 Sep; 65(18):8406-13. PubMed ID: 16166319
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of intratracheal lung cancer development by systemic delivery of E1A.
Chang JY; Xia W; Shao R; Hung MC
Oncogene; 1996 Oct; 13(7):1405-12. PubMed ID: 8875978
[TBL] [Abstract][Full Text] [Related]
10. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation.
Shao R; Lee DF; Wen Y; Ding Y; Xia W; Ping B; Yagita H; Spohn B; Hung MC
Mol Cancer Res; 2005 Apr; 3(4):219-26. PubMed ID: 15831675
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism.
Brader KR; Wolf JK; Hung MC; Yu D; Crispens MA; van Golen KL; Price JE
Clin Cancer Res; 1997 Nov; 3(11):2017-24. PubMed ID: 9815592
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
13. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
14. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
Xing X; Matin A; Yu D; Xia W; Sorgi F; Huang L; Hung MC
Cancer Gene Ther; 1996; 3(3):168-74. PubMed ID: 8725881
[TBL] [Abstract][Full Text] [Related]
15. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
Lu H; Qin H; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
[TBL] [Abstract][Full Text] [Related]
16. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
Ueno NT; Bartholomeusz C; Xia W; Anklesaria P; Bruckheimer EM; Mebel E; Paul R; Li S; Yo GH; Huang L; Hung MC
Cancer Res; 2002 Nov; 62(22):6712-6. PubMed ID: 12438271
[TBL] [Abstract][Full Text] [Related]
17. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice.
Xing X; Liu V; Xia W; Stephens LC; Huang L; Lopez-Berestein G; Hung MC
Gene Ther; 1997 Mar; 4(3):238-43. PubMed ID: 9135737
[TBL] [Abstract][Full Text] [Related]
18. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway.
Bao JJ; Le XF; Wang RY; Yuan J; Wang L; Atkinson EN; LaPushin R; Andreeff M; Fang B; Yu Y; Bast RC
Cancer Res; 2002 Dec; 62(24):7264-72. PubMed ID: 12499268
[TBL] [Abstract][Full Text] [Related]
19. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
Zhou Z; Jia SF; Hung MC; Kleinerman ES
Cancer Res; 2001 Apr; 61(8):3394-8. PubMed ID: 11309298
[TBL] [Abstract][Full Text] [Related]
20. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission.
Schiffer IB; Gebhard S; Heimerdinger CK; Heling A; Hast J; Wollscheid U; Seliger B; Tanner B; Gilbert S; Beckers T; Baasner S; Brenner W; Spangenberg C; Prawitt D; Trost T; Schreiber WG; Zabel B; Thelen M; Lehr HA; Oesch F; Hengstler JG
Cancer Res; 2003 Nov; 63(21):7221-31. PubMed ID: 14612517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
